Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Achim Steup

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Current Medical Research and Opinion|May 25, 2017
Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled studyAlain Serrie, Bernd Lange, Achim Steup
Journal of Opioid Management|December 20, 2013
A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic painMila Etropolski, Bernd Lange, Jutta Goldberg, et al.
Anesthesia and Analgesia|November 21, 2008
Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled studyRegina Kleinert, Claudia Lange, Achim Steup, et al.
Current Medical Research and Opinion|October 15, 2008
The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery Jens-Ulrich Stegmann, Horst Weber, Achim Steup, et al.
Neurourology and Urodynamics|January 23, 2018
Signs and symptoms that distinguish detrusor underactivity from mixed detrusor underactivity and bladder outlet obstruction in male patientsAndrew Gammie, Mathilde Kaper, Achim Steup, et al.
Advances in Therapy|June 18, 2010
Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back painBernd Lange, Brigitte Kuperwasser, Akiko Okamoto, et al.
Neurourology and Urodynamics|April 11, 2018
What are the additional signs and symptoms in patients with detrusor underactivity and coexisting detrusor overactivity?Andrew Gammie, Mathilde Kaper, Achim Steup, et al.
European Urology Focus|April 29, 2023
Predicting Mirabegron Treatment Response in Patients with Overactive Bladder: A Post Hoc Analysis of Data from Clinical TrialsRano Matta, Refik Saskin, Sarah Neu, et al.
Neurourology and Urodynamics|May 31, 2021
Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open-label, phase 3, dose-titration studyMałgorzata Baka-Ostrowska, David T Bolong, Cristian Persu, et al.
Neurourology and Urodynamics|January 31, 2024
Safety and efficacy of an α<sub>1</sub> -blocker plus mirabegron compared with an α<sub>1</sub> -blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: A systematic review and network meta-analysisSender Herschorn, Tufan Tarcan, Yuan-Hong Jiang, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Current Medical Research and Opinion|May 25, 2017
Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled studyAlain Serrie, Bernd Lange, Achim Steup
Journal of Opioid Management|December 20, 2013
A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic painMila Etropolski, Bernd Lange, Jutta Goldberg, et al.
Anesthesia and Analgesia|November 21, 2008
Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled studyRegina Kleinert, Claudia Lange, Achim Steup, et al.
Current Medical Research and Opinion|October 15, 2008
The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery Jens-Ulrich Stegmann, Horst Weber, Achim Steup, et al.
Neurourology and Urodynamics|January 23, 2018
Signs and symptoms that distinguish detrusor underactivity from mixed detrusor underactivity and bladder outlet obstruction in male patientsAndrew Gammie, Mathilde Kaper, Achim Steup, et al.
Advances in Therapy|June 18, 2010
Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back painBernd Lange, Brigitte Kuperwasser, Akiko Okamoto, et al.
Neurourology and Urodynamics|April 11, 2018
What are the additional signs and symptoms in patients with detrusor underactivity and coexisting detrusor overactivity?Andrew Gammie, Mathilde Kaper, Achim Steup, et al.
European Urology Focus|April 29, 2023
Predicting Mirabegron Treatment Response in Patients with Overactive Bladder: A Post Hoc Analysis of Data from Clinical TrialsRano Matta, Refik Saskin, Sarah Neu, et al.
Neurourology and Urodynamics|May 31, 2021
Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open-label, phase 3, dose-titration studyMałgorzata Baka-Ostrowska, David T Bolong, Cristian Persu, et al.
Neurourology and Urodynamics|January 31, 2024
Safety and efficacy of an α<sub>1</sub> -blocker plus mirabegron compared with an α<sub>1</sub> -blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: A systematic review and network meta-analysisSender Herschorn, Tufan Tarcan, Yuan-Hong Jiang, et al.
Pageof 2